KPV

Safety Profile

How It Works

Kpv is a tiny three-amino-acid fragment of a natural hormone (α-MSH). It gets absorbed into gut and immune cells through a specific transporter called PepT1, which is actually more active during gut inflammation, so the peptide naturally concentrates where inflammation is worst. Once inside cells, KPV blocks the main inflammation switch (NF-kB) by preventing a key protein from entering the cell nucleus where it would turn on inflammatory genes. The result is reduced production of inflammation-driving chemicals like TNF-alpha and IL-6, without the skin-darkening effects of the full hormone. This story is supported by mouse and cell studies rather than human trials (PMID 19909746, PMID 41533788, PMC 2431115).

Reported Dosing References

Schaible et al.

Studies

Ledger contains zero human RCTs, observational studies, or registry case series for KPV.

Legal Status

Not an approved drug; KPV appears within the FDA's bulk drug substances for compounding 'may present significant safety risks' documentation context, alongside discussion of peptide characterization and impurity concerns. There is no FDA approval for KPV as a drug product; the bulk-substances context signals regulatory concern about peptide-product quality in the compounding pathway rather than endorsement. Not an approved drug; KPV appears within the FDA's bulk drug substances for compounding 'may present significant safety risks' documentation context, alongside discussion of peptide characterization and impurity concerns. There is no FDA approval for KPV as a drug product; the bulk-substances context signals regulatory concern about peptide-product quality in the compounding pathway rather than endorsement. Not FDA-approved. No Drugs@FDA match, no label match, and no FAERS match for KPV in available source data. Placed on FDA Category 2 restricted compounding list under Section 503A on September 29, 2023. FDA stated it lacks human exposure data and safety information (FDA.gov). In February 2026, HHS Secretary Kennedy announced intent to reclassify approximately 14 peptides (including KPV) from Category 2 to Category 1, which would restore legal compounding access under physician prescription. As of early March 2026, formal reclassification had not been published. NOTE: HHS Secretary Kennedy announced Feb 27, 2026 that this peptide is expected to be reclassified to Category 1 (pending formal FDA publication) (compoundable). Official FDA publication pending as of March 2026.